39 studies found for:    Open Studies | "beta-Thalassemia"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "beta-Thalassemia"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  Beta-thalassemia and Microparticles
Conditions: Thalassemia Major (TM);   Thalassemia Intermedia (TI);   Microparticles (MP)Originating From Platelets, Endothelial Cells and Monocytes
Intervention: Other: Physiopathology
2 Recruiting Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major
Condition: Beta-Thalassemia
Intervention: Drug: Mozobil
3 Recruiting A Study Evaluating the Safety and Efficacy of the LentiGlobin® BB305 Drug Product in Beta-Thalassemia Major Subjects
Condition: Beta-thalassemia Major
Intervention: Genetic: LentiGlobin® BB305 Drug Product
4 Recruiting Study of ACE-536 to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia
Condition: Beta-thalassemia.
Intervention: Drug: ACE-536
5 Not yet recruiting An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients
Condition: Beta Thalassemia Major
Intervention: Drug: Deferiprone
6 Recruiting A Study Evaluating the Efficacy and Safety of LentiGlobin BB305 Drug Product in Beta-Thalassemia Major and Sickle Cell Disease
Conditions: Beta-Thalassemia Major;   Sickle Cell Disease
Intervention: Genetic: LentiGlobin BB305 Drug Product
7 Unknown  Genetic Factors Affecting the Severity of Beta Thalassemia
Condition: Beta Thalassemia
Intervention:
8 Recruiting Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.
Conditions: Beta Thalassemia Major;   Beta Thalassemia Intermedia
Interventions: Drug: Dose level 1a;   Drug: Dose level 1b;   Drug: Dose level 2;   Drug: dose level 3;   Drug: dose level 4;   Drug: dose level 5
9 Unknown  Prevalence Of Microalbuminuria Among Children Suffering From Sickle Cell Nephropathy and Sickle Cell/Beta-Thalassemia
Conditions: Sickle Cell Anemia;   Beta-Thalassemia;   Microalbuminuria
Intervention: Other: No intervention
10 Recruiting Post Hematopoietic Stem Cell Transplantation
Condition: Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major
Intervention: Drug: ICL670
11 Recruiting Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion
Condition: Thalassemia Major
Interventions: Biological: S-303 Treated Red Blood Cells (RBCs);   Biological: Conventional, untreated Red Blood Cells
12 Recruiting ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene
Condition: Confirmed Diagnosis of ß-thalassemia Major
Intervention: Genetic: Autologous CD34+ cells transduced with TNS9.3.55
13 Not yet recruiting Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)
Conditions: Beta-thalassemia;   Serum Ferritin;   Iron Chelation Therapy
Intervention: Drug: desferal, ferriprox, blood transfusion
14 Recruiting Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major
Condition: Thalassemia Major
Intervention: Genetic: unrelated CB following haplo-identical hematopoietic stem cells transplantation
15 Recruiting CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease
Conditions: Bone Marrow Failure Syndrome;   Severe Aplastic Anemia;   Severe Congenital Neutropenia;   Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Schwachman Diamond Syndrome;   Primary Immunodeficiency Syndromes;   Acquired Immunodeficiency Syndromes;   Histiocytic Syndrome;   Familial Hemophagocytic Lymphocytosis;   Lymphohistiocytosis;   Macrophage Activation Syndrome;   Langerhans Cell Histiocytosis (LCH);   Hemoglobinopathies;   Sickle Cell Disease;   Sickle Cell-beta-thalassemia
Intervention: Biological: CliniMacs (PLUS) Reagent System
16 Unknown  Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload
Conditions: Beta-thalassemia Major;   Sickle Cell Disease;   Iron Hemosiderosis
Interventions: Drug: DFP (ferriprox) and deferasirox (ICL 670);   Drug: DFP, DFO
17 Recruiting A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Conditions: Hematologic Malignancies;   Certain:;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Inherited Abnormalities of Platelets;   Disorders of the Immune System;   Histiocytic Disorders;   X-linked Adrenoleukodystrophy;   Primary Immunodeficiency Diseases;   Bone Marrow Failure;   Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
18 Unknown  Stem Cell Transplant in Sickle Cell Disease and Thalassemia
Conditions: Sickle Cell Disease;   Beta Thalassemia
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: Alemtuzumab;   Procedure: Allogeneic stem cell transplant
19 Unknown  Therapeutic Effect and Safety of Combined Hydroxyurea With Recombinant Human Erythropoietin.
Condition: Thalassemia Intermedia
Interventions: Drug: Hydroxyurea ,Epiao;   Drug: hydroxyurea, blood transfusion
20 Not yet recruiting Role of Vitamin C to Augment Iron Chelation With DFP or DFX
Conditions: Vitamin c;   Thalassemia Major;   Iron Chelation
Interventions: Drug: Vitamin C, Defriprone, deferisarox;   Drug: deferiprone , deferesarox

Previous Page Studies Shown (1-20) Next Page (21-39) Show next page of results
Indicates status has not been verified in more than two years